CancerPhase 3NCT00107627
Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery
A Phase 3 study testing Caprosyn subcuticular sutures., Monocryl subcuticular sutures. and Skin staples; in people with Cancer, run by Queensland Centre for Gynaecological Cancer at 2 sites in Australia.
Trial summary
The Skin Incision Study evaluates the efficacy of skin closure methods: skin staples and subcuticular sutures at 6 weeks and at 3 months following the operation by measuring cosmesis and pain. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cancer
- What is being tested?
- Caprosyn subcuticular sutures., Monocryl subcuticular sutures. and Skin staples;
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 2 sitesAustralia
- Study dates
- Mar 2005to Mar 2006
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Public patients at RBWH and at the Mater Public Hospital booked for elective surgery (laparotomy)
- Surgery for suspected or proven gynecological cancer
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Patient compliance and geographic proximity that allow adequate follow-up
- Signed written informed consent
- Females >=18 years of age
Who cannot join
- Unplanned laparotomy
- Laparoscopic procedures
- Unwillingness of the patient to participate in the trial
- Non-compliance of participant
- Unavailability for follow-up
- Patients who are unable or unwilling to give informed consent
Trial locations and contacts
2 sites in 1 country.
Australia2 sites
QCGC, Royal Brisbane and Women's Hospital
Herston, Queensland, 4029
Mater Adult Public Hospital
South Brisbane, Queensland, 4101
About this study
The Skin Incision Study evaluates the efficacy of skin closure methods: skin staples and subcuticular sutures at 6 weeks and at 3 months following the operation by measuring cosmesis and pain.
Read the detailed description
The Surgical Skin Incisions (SSI) is an investigator initiated, randomized, prospective (pilot) study comparing methods of skin closure following gynecological cancer surgery to evaluate:
- cosmesis;
- pain;
- adverse events.
The two most common methods of skin incision closure are staples or subcuticular sutures. Adverse events to surgical incisions represent major and significant burdens to patients and the health care system; however, no data is available comparing methods of skin closure. Surgeons have traditionally had to use personal belief rather than data or evidence to choose the method of skin incision closure. This study evaluates three types of skin closure methods:
- Skin staples;
- Monocryl subcuticular sutures;
- Caprosyn subcuticular sutures.
The objective of this trial is to evaluate the efficacy of sutures and staples at 6 weeks and at 3 months following the operation by measuring cosmesis and pain. These are assessed by both the patient and the surgeon independently using linear analogue scales and by collecting information on analgesic medications taken by the patient. The safety of the staples and sutures will be expressed by the incidence of adverse events following surgery. Post-operative events such as wound infection, other wound complications, grade of inflammation, hemorrhage and other complications will be graded according to the Common Toxicity Criteria (CTC version 3) and recorded.
Investigators will invite public patients with proven or suspected gynecological cancer from Royal Brisbane and Women's Hospital and Mater Hospital (RBWH) that are booked to have elective surgery and that meet the selection criteria to participate in this study.
This is a pilot study to generate data for a definitive randomized study. Ninety (90) patients are required for recruitment to the pilot study.
The type of closure method patients will receive will be allocated using a randomization process. Three equally sized study arms of 30 patients will have their surgical incision closed with either surgical staples, Monocryl or Caprosyn. Additionally, patients will be stratified by site so as to remove selection bias.
All tests and assessments before and after the operation are standard of care. These results will be recorded. No additional tests or assessments will be performed for the aim of this trial.
Randomization, data management and statistical analysis will be coordinated by the Queensland Centre for Gynaecological Cancer. Statistical analysis will include calculating mean values and standard deviations for scores for each group at each assessment. Chi-square tests will be used to compare differences in proportions of patients who did or did not experience adverse events at each time point.
Results of this trial will be presented at scientific meetings at a national and international level and at educational meetings with medical staff. The results of this trial will also be submitted for publishing. The study will generate data for a definitive randomized study.
- Conditions
- Cancer
- Being tested
- Caprosyn subcuticular sutures., Monocryl subcuticular sutures., Skin staples;
- Keywords
- Gynaecological Cancer, Surgical Staples, Subcuticular Sutures
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Caprosyn subcuticular sutures.Other
Also called Sutures, Stitches
Caprosyn subcuticular sutures.
Monocryl subcuticular sutures.Other
Also called Sutures,, Stitches
Monocryl subcuticular sutures.
Skin staples;Other
Also called Staples
Skin staples;
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Skin staples; Receives: Other: Skin staples; |
| 2 | Active comparator | Monocryl subcuticular sutures. Receives: Other: Monocryl subcuticular sutures. |
| 3 | Active comparator | Caprosyn subcuticular sutures. Receives: Other: Caprosyn subcuticular sutures. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy of the device as measured by cosmesis, pain and requirement for analgesic and antibiotic medication
Measured: 6 weeks after surgery
Secondary outcomes (2)
To evaluate the wound healing process (normal or delayed), cosmesis and pain, requirement for surgical or medical intervention (analgesic and antibiotic medication)
Measured: 3 months after surgery
Safety of the device as expressed in the incidence of adverse events following surgery
Measured: 6 weeks after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2005 (estimated)
- Study startMar 2005
- Primary completionMar 2006
- Study completionMar 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Queensland Centre for Gynaecological Cancer
- Sponsor type
- Other government
- Investigators
- Andreas Obermair, Principal investigator, Queensland Centre for Gynaecological Cancer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00107627
- Sponsor's protocol ID
- SIS001
- Status last verified
- Jun 2009
- First submitted
- 6 Apr 2005
- Last updated
- 25 Jun 2009
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery
- ClinicalTrials.gov ID
- NCT00107627
- Acronym / sponsor ID
- SIS001
- Conditions
- Cancer
- Keywords
- Gynaecological Cancer, Surgical Staples, Subcuticular Sutures
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Queensland Centre for Gynaecological CancerOther government
- Study start
- Mar 2005
- Primary completion
- Mar 2006 (actual)
- Study completion
- Mar 2006 (actual)
- First posted
- 7 Apr 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Skin Incision Study evaluates the efficacy of skin closure methods: skin staples and subcuticular sutures at 6 weeks and at 3 months following the operation by measuring cosmesis and pain.
Detailed description
The Surgical Skin Incisions (SSI) is an investigator initiated, randomized, prospective (pilot) study comparing methods of skin closure following gynecological cancer surgery to evaluate:
- cosmesis;
- pain;
- adverse events.
The two most common methods of skin incision closure are staples or subcuticular sutures. Adverse events to surgical incisions represent major and significant burdens to patients and the health care system; however, no data is available comparing methods of skin closure. Surgeons have traditionally had to use personal belief rather than data or evidence to choose the method of skin incision closure. This study evaluates three types of skin closure methods:
- Skin staples;
- Monocryl subcuticular sutures;
- Caprosyn subcuticular sutures.
The objective of this trial is to evaluate the efficacy of sutures and staples at 6 weeks and at 3 months following the operation by measuring cosmesis and pain. These are assessed by both the patient and the surgeon independently using linear analogue scales and by collecting information on analgesic medications taken by the patient. The safety of the staples and sutures will be expressed by the incidence of adverse events following surgery. Post-operative events such as wound infection, other wound complications, grade of inflammation, hemorrhage and other complications will be graded according to the Common Toxicity Criteria (CTC version 3) and recorded.
Investigators will invite public patients with proven or suspected gynecological cancer from Royal Brisbane and Women's Hospital and Mater Hospital (RBWH) that are booked to have elective surgery and that meet the selection criteria to participate in this study.
This is a pilot study to generate data for a definitive randomized study. Ninety (90) patients are required for recruitment to the pilot study.
The type of closure method patients will receive will be allocated using a randomization process. Three equally sized study arms of 30 patients will have their surgical incision closed with either surgical staples, Monocryl or Caprosyn. Additionally, patients will be stratified by site so as to remove selection bias.
All tests and assessments before and after the operation are standard of care. These results will be recorded. No additional tests or assessments will be performed for the aim of this trial.
Randomization, data management and statistical analysis will be coordinated by the Queensland Centre for Gynaecological Cancer. Statistical analysis will include calculating mean values and standard deviations for scores for each group at each assessment. Chi-square tests will be used to compare differences in proportions of patients who did or did not experience adverse events at each time point.
Results of this trial will be presented at scientific meetings at a national and international level and at educational meetings with medical staff. The results of this trial will also be submitted for publishing. The study will generate data for a definitive randomized study.
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Other: Skin staples;Skin staples; |
| 2 | Active comparator | Other: Monocryl subcuticular sutures.Monocryl subcuticular sutures. |
| 3 | Active comparator | Other: Caprosyn subcuticular sutures.Caprosyn subcuticular sutures. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Public patients at RBWH and at the Mater Public Hospital booked for elective surgery (laparotomy)
- Surgery for suspected or proven gynecological cancer
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Patient compliance and geographic proximity that allow adequate follow-up
- Signed written informed consent
Key exclusion criteria (6 listed)
- Unplanned laparotomy
- Laparoscopic procedures
- Unwillingness of the patient to participate in the trial
- Non-compliance of participant
- Unavailability for follow-up
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Caprosyn subcuticular sutures.Also: Sutures, StitchesCaprosyn subcuticular sutures. | Other | 3 |
| Monocryl subcuticular sutures.Also: Sutures,, StitchesMonocryl subcuticular sutures. | Other | 2 |
| Skin staples;Also: StaplesSkin staples; | Other | 1 |
Primary outcome
Efficacy of the device as measured by cosmesis, pain and requirement for analgesic and antibiotic medication
Time frame: 6 weeks after surgery
2 secondary outcomes
To evaluate the wound healing process (normal or delayed), cosmesis and pain, requirement for surgical or medical intervention (analgesic and antibiotic medication)
Time frame: 3 months after surgery
Safety of the device as expressed in the incidence of adverse events following surgery
Time frame: 6 weeks after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2009.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andreas Obermair principal investigator
Queensland Centre for Gynaecological Cancer
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Caprosyn subcuticular sutures., Monocryl subcuticular sutures. and Skin staples; in people with Cancer, run by Queensland Centre for Gynaecological Cancer at 2 sites in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jun 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy of the device as measured by cosmesis, pain and requirement for analgesic and antibiotic medication (time frame: 6 weeks after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2009.